The Sarilumab (anti-IL-6) study for intermediate and posterior uveitis has been initiated in our centre for Switzerland. Janu 28 2014

The Sarilumab (anti-IL-6) study for intermediate and posterior uveitis has been initiated in our centre for Switzerland.

NEW ADDRESS. Our office moves in August 2013! Augu 1 2013

As of august 1st 2013, our office moves to a new facility at Avenue du Léman 32 in Lausanne. For more info click on "NEW ADDRESS" here above.

Prof de Smet is the new treasurer of the International Uveitis study group (IUSG) May 1 2013

The International Uveitis Study Group (IUSG) is the oldest and most prestigious association of specialists in the field of ocular inflammation.

Sanofi sarilumab Janu 1 2013

Professor De Smet became the coordinator of the European study sarilumab for uveitis which do not adequately respond to the usual therapies. Sarilumab is a monoclonal antibody directed against the interleukin (IL)-6 receptor, a receptor involved in the inflammatory process.

1 2 3 4 5 previous next